Navigation Links
ARMGO Pharma Receives $1 Million Award from MDA to Support Advancement of Rycal Compound ARM210 as a Novel Treatment for Duchenne Muscular Dystrophy
Date:4/17/2013

TARRYTOWN, N.Y. and TUCSON, Ariz., April 17, 2013 /PRNewswire/ -- ARMGO Pharma and the Muscular Dystrophy Association (MDA) today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy (DMD).  The funding award to ARMGO Pharma comes from MDA Venture Philanthropy (MVP), part of MDA's translational research program.

The project being advanced by ARMGO Pharma is focused on a novel class of small molecule drugs known as Rycals™ which target the Ryanodine Receptor (RyR), an intracellular calcium channel that becomes leaky in disease states including muscular dystrophy, contributing to loss of muscle strength and function.  Rycals have been shown in animal models of muscle disease to repair RyR-mediated calcium leak and thereby improve specific muscle force and exercise capacity.  ARMGO Pharma's experimental proprietary drug ARM210 has been selected by the company from its library of Rycal candidates for preclinical advancement as a potential treatment for DMD.  With its unique mechanism of action and oral delivery formulation, ARM210 has the potential to provide benefit across skeletal muscle, diaphragm and heart muscle in DMD patients regardless of genetic background, both as a mono-therapy as well as in conjunction with other treatments.

DMD is one of nine types of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles.  Caused by mutations in the gene that makes dystrophin, a protein that normally protects muscle cells and keeps them intact, DMD eventually weakens all voluntary muscles, and the heart and breathing muscles.  DMD affects approximately 1 in 3,500 boys with an estimated patient population exceeding 50,000 worldwide."We are very pleased to have been selected by the MDA to receive funding which will support the advancement of ARM210," said Dr. Sapan Shah , President and CEO of ARMGO Pharma.  "We are excited at the possibility to expand our Rycal program into skeletal muscle diseases such as DMD, where new treatment options for patients are desperately needed." 

"This is a very interesting potential therapeutic," said Jane Larkindale, MDA's vice president for research.  "It works in a different way than the other potential therapeutics in development, which suggests that in addition to being effective on its own, it also might be able to be added on to other treatments, when other treatments become available."

About ARMGO Pharma
ARMGO Pharma, Inc., is a privately held biopharmaceutical company dedicated to applying original, targeted science to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, musculoskeletal, and neurological disorders. The company's proprietary drugs, known as Rycals™, are a new class of oral agents that repair calcium leak through the ryanodine receptor calcium-release channel (RyR), which is located on the sarcoplasmic/endoplasmic reticulum of the cell.  ARMGO Pharma has been awarded an exclusive, worldwide license from Columbia University for its RyR technology.  ARMGO Pharma's lead Rycal program ARM036 is in Phase 2 clinical studies for the treatment of heart failure and arrhythmias.  Development and commercial rights for ARMGO's Rycal drugs in cardiovascular and skeletal muscle indications outside of the US and Japan have been exclusively licensed to Les Laboratoires Servier (SERVIER).About MVP
MDA Venture Philanthropy program, the drug development arm of the Association's translational research program, made the award to ARMGO. The grant will fund laboratory work which ARMGO must complete before the biotech can submit an investigational new drug (IND) application to the U.S. Food and Drug Administration. An IND application is required by the FDA before a new drug can move to clinical trials in humans.

About MDA
MDA is the nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education.In addition to funding more than 250 research projects worldwide, MDA maintains a national network of 200 medical clinics; facilitates hundreds of support groups for families affected by neuromuscular diseases; and provides local summer camp opportunities for thousands of youngsters living with progressive muscle diseases.For more information, visit mda.org and follow MDA on Facebook (facebook.com/MDAnational) and Twitter (@MDAnews).

RELATED LINKS

http://www.armgo.comhttp://www.mda.orgContact: Dr. Sapan Shah

Roxan Olivas CEO, ARMGO Pharma

MDA Vice President — Public Relations(914) 425-0000

(520) 529-5305info@armgo.com 

rolivas@mdausa.org


'/>"/>
SOURCE ARMGO Pharma; Muscular Dystrophy Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. VIVUS Announces FDA Approval of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies
2. New White Paper Details What Compounding Pharmacies Must Know to Prepare for FDA Inspections
3. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
4. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
5. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
6. Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
7. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
8. CPhI und PharmaEvolution.com werden die Pharmaindustrie in Monats- und Jahresberichten analysieren
9. CPhI et PharmaEvolution.com sapprêtent à analyser lindustrie pharmaceutique dans des rapports mensuels et annuels
10. CPhI y PharmaEvolution.com analizarán la industria farmacéutica con informes mensuales y anuales
11. Distribution on the pharmaceutical market in Poland 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Mass. , Feb. 12, 2016   HeartWare ... a conference call and webcast to discuss its financial ... 31, 2015, on Thursday, February 25, 2016 at 8:00 ... results prior to the conference call and webcast.  On ... company,s financial results, highlights from the fourth quarter and ...
(Date:2/12/2016)... 12, 2016  Memorial Hermann Health System has teamed ... to bring a one-of-a-kind experience to pediatric patients ... technologies such as 360-degree video and Google Cardboard, Howard ... literally – giving the patients and their families an ... all caught on video . Memorial ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. ... Macrogen, Inc. today announced they will form a ... for precision medicine in cancer. The goal of ... digital-sorting technology with Macrogen,s high-throughput Next Generation Sequencing ... the Clinical Laboratory Improvement Amendments (CLIA) of 1988 ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... , ... Hidden Cypress in Sun City is the place to be on March 3rd to ... Weniger will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting ... pricing on offers. In addition, prizes will be given away and light refreshments will be ...
(Date:2/13/2016)... ... , ... The producers of Enterprises TV are pleased to present ... world of instantaneous consumption proves very convenient for businesses. With new technologies constantly becoming ... which pollutes our air, water, and soil. It can also threaten the lives of ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... top Clinical Data Management Solution Providers list for its expertise in eClinical Solutions. ... domain expertise to serve the technology needs of global clients. DDi provides smarter ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, 2016. ...
(Date:2/12/2016)... ... ... Coco Libre, the maker of coconut water beverages with a purpose, is ... Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, a ... suite, held this year at the W Hollywood Hotel, has become a pre-show “must” ...
Breaking Medicine News(10 mins):